And the Studies Prove It
The current official stance is that there is no real treatment for COVID-19. If you get it, you are told to just go home and tough it out…until/unless you start finding it hard to breathe, or develop other severe symptoms requiring hospitalization. Fortunately, in the vast majority of cases (something like 80%) symptoms are mild, moderate or non-existent. And, moreover, the mortality rate is about half of one percent.
“We’ve seen some data on about 17,000 cases and, overall, 82 percent of those are mild, 15 percent of those are severe and 3 percent of those are classified as critical,” - Dr. Maria Van Kerkhove, head of the WHO’s Health Emergencies Program.
That’s all comforting. But wouldn’t be a lot more comforting to know there are medicines that can prevent infection, stop it progressing if we do get it and treat it successfully if it does develop into an advanced, serious case?
“The current best estimates for the infection fatality risk are between 0.5% and 1%,” says Caitlin Rivers, an epidemiologist at the Johns Hopkins Center for Health Security.”
The focus everywhere at the moment seems to be on behavioral precautions (social distancing, masks, protocols for opening businesses and schools — or not) and the many accelerated vaccine development projects worldwide. And of course that is all important stuff. However, there have also been some efforts to identify and verify any promising treatments (though you wouldn’t know it based only on mainstream media coverage). The need for speed in introducing effective treatments means efforts are mainly directed at re-purposing existing drugs with known reliability and safety records rather than starting from scratch. And we’re starting to see some progress. Here are some frontrunners:
Ivermectin & Doxycycline
Haven’t heard of these? Not surprising. It’s a sad indictment of what passes for journalism today that most of us haven’t, unless we’re medical professionals. Treatment of severe cases with this paired approach described as “astounding” in Bangladesh has led to studies and reviews of data being initiated that are ongoing now. Those include India’s national research agency, the Indian Council of Medical Research (ICMR), and ICON (Ivermectin in COvid Nineteen) study: Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID19.
“We have got astounding results. Out of 60 COVID-19 patients, all recovered as the combination of the two drugs were applied”, said Professor Dr Md Tarek Alam, the head of medicine department at private Bangladesh Medical College Hospital (BMCH).
Hydrochloroquine + Azithromycin + Zinc
Unless you’ve been avoiding media for several months (and who could blame you?) you’ve no doubt heard of hydrochloroquine. And you may have also discovered that if you mention, share a post or even “like” a post that speaks of it positively with regard to COVID-19 on Facebook, you will be notified that that item has been blocked because it contains false information. Even Yale University School of Public Health Dean Sten H. Vermund, MD, PhD apparently was inundated with sufficient pressure that he felt obliged to publish a statement mitigating response to Dr Harvey Risch’s recent publication on the topic of favorable outcomes in the use of hydroxychloroquine (HCQ) in COVID-19 out-patient therapy.
But the evidence strongly suggests merit to HCQ/CQ, especially when combined with azithromycin (“Z-Pack”, a common antibiotic) and zinc (an alternative ingredient may also prove effective, quercetin). So much so that studies have been undertaken to independently assess this line of treatment. Yet if you even mention that fact you are liable to be attacked, censored and your maternal lineage called into question. Evidence and studies include:
- Does zinc supplementation enhance the clinical efficacy of chloroquine/hydroxychloroquine to win today’s battle against COVID-19? in Elsevier September 2020
- Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient Setting
- Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19
- Outpatient Study Finds that Combination of Zinc, Hydroxychloroquine, and Azithromycin Is Associated with Less Hospitalizations and Death for COVID-19 Patients — Derwand, Scholz & Zelenko
- Breaking COVID-19 News, July 14, By Dr. Elizabeth Lee Vliet, Former Director, Association of American Physicians and Surgeons
Zinc, well-known as an antiviral, seems to be an integral part of the treatment, as shown here:
Derwand, Scholz and Zelenko are leaders in this area of study. Dr. Zelenko explains, in a July 15 release:
“These three medications are affordable, available in pill form, and work in synergy against COVID-19,” said Zelenko. “Hydroxychloroquine’s main function within this treatment approach is to allow zinc to enter the cell. Zinc is the virus killer, and azithromycin prevents secondary bacterial infection in the lungs and reduces the risk of pulmonary complications.”
“Hydroxychloroquine’s main function is to allow zinc to enter the cell, while zinc is a virus killer,” Zelenko added. “Azithromycin prevents secondary bacterial infection in the lungs, and reduces the risk of pulmonary complications. So zinc is the bullet, hydroxychloroquine is the gun, and azithromycin is the protective vest.”
In light of the overwhelming data supporting this line of investigation, the medical community is beginning to question more and more why there seems to be an almost universal condemnation of even considering the use of a commonly-prescribed drug with a safe track record of over 65 years.
Since it was approved more than 65 years ago for malaria, and later for lupus and rheumatoid arthritis, HCQ has been safely used worldwide in hundreds of millions of patients. More than 15 years ago, in the 2002–2003 SARS-CoV-1 outbreak, CDC conducted in-vitro studies that showed HCQ was a potent anti-viral agent. Since the SARS-CoV-2 virus, initially recognized in China, has been spreading around the world, HCQ has been widely used in dozens of countries as a safe and effective treatment for the novel coronavirus causing COVID-19.
In all reports, including the CDC findings published in 2005, HCQ’s most important effect is to block viral entry into the cells and viral replication IF given within the first 5 days of symptoms. Restricting HCQ use to only critically ill hospitalized patients has been one of the reasons for the high U.S. COVID death rate compared to countries using it prophylactically and early in the viral illness. ALL viral illness we treat respond best to anti-viral medication begun early, not late when patients are critically ill.
The U.S. situation is out of control, with people dying and businesses shut down because of FDA roadblocks and governors’ restrictive orders illegally overriding normal FDA regulations that allow physicians to prescribe ANY FDA-approved medication (including HCQ) however they deem medically appropriate. Physicians in many states also face threats of investigation by their state medical boards for prescribing HCQ for COVID-19, and state pharmacy boards direct pharmacists to refuse to dispense HCQ for COVID patients. Such political interference with doctors’ ability to treat patients has never happened before in my medical career.” — Dr. Elizabeth Lee Vliet, Former Director, Association of American Physicians and Surgeons
So be safe, keep your social distance, wear your mask…but stay open to what science tells you — and not just the science approved by Facebook and the MSM.
What happens if you catch the new coronavirus?
A new coronavirus that emerged in China late last year has spread to at least 188 countries on six continents, with the…
Antibody Tests Point To Lower Death Rate For The Coronavirus Than First Thought
Mounting evidence suggests the coronavirus is more common and less deadly than it first appeared. The evidence comes…
ICMR-India's National Research Agency-Investigating Ivermectin & Doxycycline as Potential Treatment…
India's national research organization known as the Indian Council of Medical Research (ICMR) is now reviewing the…
Bangladesh Medical Team Claims Ivermectin With Doxycycline Clears COVID-19
A Bangladeshi medical team is claiming that their research on the combination of two widely used and common drugs has…
ICON (Ivermectin in COvid Nineteen) study: Use of Ivermectin is Associated with Lower Mortality in…
Abstract Importance: No therapy to date has been shown to improve survival for patients infected with SARS-CoV-2…
COVID-19 Outpatients - Early Risk-Stratified Treatment with Zinc Plus Low Dose Hydroxychloroquine…
Objective: To describe outcomes of patients with coronavirus disease 2019 (COVID-19) in the outpatient setting after…
YSPH Statement Regarding Hydroxychloroquine
Dr. Harvey Risch is a distinguished cancer epidemiologist who has opined on the topic of hydroxychloroquine (HCQ) and…
Early Outpatient Treatment of Symptomatic, High-Risk Covid-19 Patients that Should be Ramped-Up…
Abstract. More than 1.6 million Americans have been infected with SARS-CoV-2 and >10 times that number carry…
The Use of Zinc, Hydroxychloroquine, and Azithromycin are Associated with Less Death in COVID-19…
Find the direct link for download here . New York, NY July 2, 2020 - Dr. Vladimir Zelenko, a New York based primary…
Newly Published Outpatient Study Finds that Early Use of Zinc, Hydroxychloroquine and Azithromycin…
Dr. Vladimir Zelenko, a New York based primary care physician, announced that a retrospective analysis based on his…